Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older

Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older

Abstract Introduction Respiratory syncytial virus (RSV) is a major cause of acute respiratory illness. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved in Japan to prevent RSV-related diseases in older adults in 2024. This study evaluated the cost-effectiveness of the RSVpreF...

Full description

Saved in:
Bibliographic Details
Main Authors: Kosaku Komiya, Yoko Hirano, Kazumasa Kamei, Asuka Yoshida, Junko Morii, Ryohei Kobayashi, Reiko Sato
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Infectious Diseases and Therapy
Subjects:
Cost-effectiveness
Japan
Older adults
Respiratory syncytial virus
RSV
RSVpreF
Online Access:https://doi.org/10.1007/s40121-025-01177-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-025-01177-4

Similar Items